Please sign in to follow a disease.
Uterine carcinoma
MONDO:0005213A carcinoma involving a uterus.
Also known as: carcinoma of uterus, uterus carcinoma
3360 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 704 trials in this tab.
-
Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?
Vaccine OngoingThis phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…
Phase 1 • Sponsor: Herbert Lyerly • Aim: Vaccine
Last updated Sep 04, 2026 00:00 UTC
-
Quantum-Powered vaccine takes on endometrial cancer
Vaccine By invitation onlyThis early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with stan…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Immunotherapy drug nivolumab tested against tough cervical cancers
Disease control OngoingThis phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC
-
Can a smartphone app help cancer patients kick the habit?
Disease control OngoingThis phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…
Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase 1/2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can fewer, stronger radiation doses spare the bowel in gynecologic cancers?
Disease control OngoingThis pilot study tests whether hypofractionated radiation therapy, which gives higher doses over fewer sessions, is a practical option for people with non-metastatic cervical or endometrial cancer after hysterectomy. Researchers will measure bowel and urinary side effects using p…
Sponsor: University of Utah • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingThis phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New program helps cancer survivors fight heart disease with exercise
Disease control OngoingThis study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for advanced cervical cancer: MK-2870 trial launches
Disease control OngoingThis Phase 3 trial compares a new drug, MK-2870, against standard treatments for people with recurrent or metastatic cervical cancer that has progressed after initial therapy. About 686 participants will receive either MK-2870 or a doctor-chosen standard treatment. The main goal …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug takes on chemo in major trial
Disease control OngoingThis study tests a new drug, MK-2870, against standard chemotherapy in about 710 people with endometrial cancer that has worsened after platinum chemo and immunotherapy. The goal is to see if MK-2870 helps people live longer and delays cancer growth. Participants are randomly ass…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill may keep endometrial cancer at bay longer
Disease control OngoingThis study tests whether the drug selinexor can help keep advanced or recurrent endometrial cancer from growing back after initial chemotherapy. About 276 adults whose cancer has a normal p53 gene and who responded to platinum-based chemo will receive either selinexor or a placeb…
Phase 3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase 1/2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise for recurrent ovarian cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill takes on tough cancers in first human test
Disease control OngoingThis early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…
Phase 1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase 1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for aggressive uterine cancer: targeted drug trial shows promise
Disease control OngoingThis study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of ut…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Measles virus hijacks stem cells to attack ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control By invitation onlyThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo shows promise against tough cancers
Disease control OngoingThis early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…
Phase 1 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for advanced cervical cancer: drug trial targets remaining risk
Disease control OngoingThis study tests an experimental drug called volrustomig in 37 women with high-risk, locally advanced cervical cancer that hasn't gotten worse after standard chemotherapy and radiation. The goal is to see if the drug can help keep the cancer from coming back or spreading. Partici…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Heated chemo during surgery: a new hope for ovarian cancer?
Disease control OngoingThis early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated che…
Early phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Cancer drug targets genetic weakness in advanced tumors
Disease control OngoingThis phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase 1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control By invitation onlyThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for endometrial cancer: immunotherapy and targeted drug combo tested
Disease control OngoingThis Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Cancer drug olaparib gets a makeover: which pill works best?
Disease control OngoingThis phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy duo takes on cervical cancer in new trial
Disease control OngoingThis Phase 2 trial tests whether adding relatlimab to nivolumab (both immunotherapy drugs) works better than nivolumab alone for locally advanced cervical cancer. About 77 women with stage IIB to IVA cervical cancer will receive either the combination or nivolumab alone before st…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Engineered immune cells target Hard-to-Treat cancers in new trial
Disease control PausedThis study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug spartalizumab gets extended safety check in ongoing patients
Disease control OngoingThis study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can Immune-Boosting drugs tame recurrent endometrial cancer?
Disease control OngoingThis trial investigates whether the immunotherapy drug avelumab, given alone or combined with talazoparib or axitinib, can shrink tumors or slow disease progression in women with recurrent or persistent endometrial cancer. Participants have specific tumor types, including those w…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase 2/3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Cancer patients get extended access to promising immunotherapy
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for endometrial cancer: drug combo shows promise
Disease control OngoingThis study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see how safe and tolerable the treatment is. About 85 people in…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug takes aim at NF1-Mutated cancers
Disease control OngoingThis phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo tackles Platinum-Resistant gynecologic cancers
Disease control OngoingThis phase 2 trial tests whether combining internal radiation (brachytherapy) with two immunotherapy drugs, durvalumab and tremelimumab, can help women with gynecologic cancers that are resistant to platinum chemotherapy. The study includes 9 participants with ovarian, endometria…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail targets advanced cancers in early trial
Disease control OngoingThis Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer patients get continued access to lifesaving drug in new study
Disease control OngoingThis study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Targeted drug palbociclib tested against cancers with specific genetic flaw
Disease control OngoingThis phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Pushing a weighted sled may help cancer patients build muscle and lose fat
Disease control OngoingThis pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immunotherapy combo tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Cancer patients get continued access to key therapy in extension study
Disease control OngoingThis study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…
Phase 1/2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control PausedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase 1/2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New oral drug aims to tackle Hormone-Driven cancers
Disease control OngoingThis study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control By invitation onlyThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase 1/2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with resistant tumors: drug combo enters safety trial
Disease control OngoingThis early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat endometrial cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 50 people with endometrial cancer that has returned or not responded to platinum chemotherapy. The drug works by delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or d…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental cell therapy aims to fight advanced cancers
Disease control CancelledThis study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…
Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Precision radiation may cut side effects in cervical cancer
Disease control OngoingThis study tests online adaptive radiotherapy, a type of radiation that adjusts in real-time to target cervical cancer more precisely. By using smaller treatment margins, doctors hope to reduce side effects while still effectively treating the tumor. The trial involves 30 adults …
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug injected into tumors shows promise in early trial
Disease control PausedThis early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control OngoingThis study tested a combination of two drugs—mirvetuximab soravtansine and pembrolizumab—in 18 people with a specific type of uterine cancer (endometrial cancer) that had returned or persisted and was microsatellite stable (MSS). The goal was to see if the combo could shrink tumo…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Fewer trips to the hospital? new cervical cancer radiation trial aims to cut treatment time
Disease control OngoingThis study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for cervical cancer patients also receiving chemotherapy. The goal is to see if the shorter schedule is just as safe and effective, while reducing the number of hospit…
Sponsor: Siriraj Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise in shrinking cervical tumors before surgery
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before hysterectomy can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive three cycles of the combination, then surgery if the tumor …
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase 1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase 1/2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a simpler lymph node check replace major surgery for endometrial cancer?
Disease control OngoingThis study compares two surgical approaches for women with middle-to-high risk endometrial cancer that hasn't spread beyond the uterus. One group gets sentinel lymph node sampling (removing only a few key nodes), while the other gets standard pelvic lymphadenectomy (removing many…
Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase 1/2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy for endometrial cancer shows promise in early trial
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy is safe and feasible for people with high-intermediate risk endometrial cancer. About 45 participants who have already had surgery to remove the uterus wil…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ZW191 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…
Phase 1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy shows promise in battle against aggressive uterine cancer
Disease control OngoingThis Phase 3 trial compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature (dMMR). The goal is to see if pembrolizumab can better delay cancer growth and impro…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug LP-184 tested on tough cancers: hope for Late-Stage patients
Disease control OngoingThis study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…
Phase 1/2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cell therapy for advanced gynecological cancers halted before start
Disease control CancelledThis study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…
Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Tiny paclitaxel particles aim to hit tumors harder
Disease control OngoingThis early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …
Phase 1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a Nurse-Led program transform Women's health in hong kong?
Disease control OngoingThis trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug shrinks tumors in advanced cancers
Disease control OngoingThis study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug for immunotherapy side effects never tested: trial withdrawn
Disease control CancelledThis phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…
Phase 2 • Sponsor: Douglas Johnson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo takes on advanced cancers in early trial
Disease control OngoingThis study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
MRI-Guided radiation: a sharper weapon against gynecologic cancer?
Disease control OngoingThis study tests new MRI-based tools to make brachytherapy—a type of internal radiation—more accurate for gynecologic cancer. Researchers will compare standard brachytherapy with an MRI-guided version in 49 patients to see if it improves radiation delivery. The goal is better tum…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer drug combo trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase 2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for advanced cancers
Disease control OngoingThis early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer drug ALK-N001 enters early human testing
Disease control PausedThis early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…
Phase 1 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase 1/2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control OngoingThis early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…
Phase 1 • Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could chemo after surgery beat endometrial cancer relapse?
Disease control OngoingThis study looks at whether giving chemotherapy after surgery can help people with early-stage (stage I-II) endometrial cancer who have a higher risk of the cancer coming back. About 244 patients will either receive six cycles of carboplatin and paclitaxel or simply be observed. …
Phase 2 • Sponsor: Danish Gynecological Cancer Group • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New immunotherapy combo tested for incurable cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…
Phase 1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for advanced cancer? early trial of 3D185 begins
Disease control OngoingThis early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…
Phase 1 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New device aims to prevent vaginal scarring after cancer radiation
Disease control By invitation onlyThis study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The g…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young sarcoma patients: experimental drug combo targets tough tumors
Disease control PausedThis study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug HRS-6209 tested in advanced cancer patients
Disease control OngoingThis early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…
Phase 1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Two-Antibody combo takes on advanced cancers
Disease control OngoingThis study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for cervical cancer: drug combo targets tumors resistant to immunotherapy
Disease control OngoingThis phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease prog…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug IBI363 aims to supercharge immune system against tough cancers
Disease control OngoingThis early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New targeted therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…
Phase 1/2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for ovarian cancer: drug may delay return of disease
Disease control OngoingThis study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill shows promise against lung cancer in early trial
Disease control OngoingThis study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase 1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug duo aims to tackle returning cervical cancer
Disease control OngoingThis Phase 2 trial is testing whether combining two drugs, niraparib and dostarlimab, can help shrink or control cervical cancer that has come back or spread. About 66 women with recurrent or progressive cervical cancer will receive the treatment. The goal is to see how many resp…
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase 1/2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hitchhiking drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase 1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Turmeric trial for cervical precancer pulled before it began
Disease control CancelledThis early-phase trial aimed to test whether curcumin (the active compound in turmeric) could safely help treat cervical precancer (CIN3). It planned to give 500 mg of curcumin twice daily for 12 weeks to women with CIN3. However, the study was withdrawn before enrolling any part…
Early phase 1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…
Phase 1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase 1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cell therapy aims to boost cancer fight
Disease control OngoingThis early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…
Phase 1/2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…
Phase 1/2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…
Phase 1/2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New antibody combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…
Phase 1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Phase 1/2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …
Phase 1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for rare lung cancer subtype
Disease control OngoingThis phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Immunotherapy drug dostarlimab takes on chemo in advanced endometrial cancer trial
Disease control OngoingThis phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…
Phase 3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can digital nutrition help cancer patients fight malnutrition?
Disease control OngoingThis study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …
Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 26, 2026 14:40 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to find the best way to catch HPV cancers early in HIV patients
Diagnosis OngoingThis study looks at which tests work best to find early signs of HPV-related cancer in the cervix or anus of people living with HIV. About 1,586 participants from Mexico and Puerto Rico will be tested using different methods, including HPV tests and cell samples. The goal is to c…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis CancelledThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis CancelledThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new tracer light up tumors better than standard PET scans?
Diagnosis By invitation onlyThis trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis PausedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
New study aims to improve cervical cancer detection in HIV-Positive women
Diagnosis OngoingThis study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…
Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Could a DIY swab replace the pelvic exam for cervical cancer screening?
Diagnosis OngoingThis study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor's sample. It involves 750 women referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable alternative to traditional pelvic exa…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple ultrasound predict immunotherapy success?
Diagnosis PausedThis study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New MRI technique could sharpen views of gynecologic tumors
Diagnosis OngoingThis study tests a new type of DCE-MRI that takes pictures faster and reduces blurring from movement. The goal is to see if it gives clearer images of gynecologic tumors than traditional MRI. About 24 women with gynecologic cancer and healthy volunteers will take part. The new sc…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
Can a simple HPV test replace colposcopy for cervical cancer Follow-Up?
Diagnosis OngoingThis study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Simple blood test could transform cancer monitoring
Diagnosis OngoingThis study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New PET scan agent could predict cancer therapy success, but trial never started
Diagnosis CancelledThis pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…
Early phase 1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Could mailing HPV tests boost screening rates?
Diagnosis OngoingThis study looks at whether offering HPV self-sampling kits by mail, pharmacy, or clinic can make cervical cancer screening easier. One thousand women aged 25-65 in Quebec will try different ways to get and return the kit. The goal is to see which method works best and if women f…
Sponsor: Université de Sherbrooke • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
One shot to stop cancer: HPV vaccine study could change global prevention
Prevention OngoingThis study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …
Phase 4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Can reminders and education prevent cervical cancer? a new trial aims to find out.
Prevention OngoingThis trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention OngoingThis study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…
Phase 3 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
At-Home cervical cancer screening could save lives in rural uganda
Prevention OngoingThis study looks at whether women in rural Uganda can screen themselves for cervical cancer using a simple HPV test at home. Over 2,500 women aged 25-49 will collect their own samples during community health campaigns. The goal is to see if this approach increases screening rates…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
Could a simple HPV test every 5 years replace frequent pap smears?
Prevention OngoingThis study compares two ways to screen for cervical cancer: a Pap smear every 2.5 years versus an HPV test every 5 years. Over 76,000 women aged 25-69 in Australia are taking part, including those who received the HPV vaccine and those who did not. The goal is to see if the less …
Sponsor: VCS Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
Probiotics may shield cancer patients from Immunotherapy's gut woes
Prevention PausedThis study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …
Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
One-Shot wonder? huge study tests single HPV vaccine dose
Prevention OngoingThis large study of nearly 28,000 girls aged 12-16 tests whether a single dose of HPV vaccine works as well as the standard two doses to prevent persistent infection with the virus types that cause most cervical cancers. If one dose is enough, it could lower costs and simplify va…
Phase 4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 26, 2026 14:06 UTC
-
Poetry therapy aims to bring purpose to LGBTQ+ cancer patients at end of life
Symptom relief OngoingThis study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 09, 2026 15:00 UTC
-
Can a text message help depressed cancer survivors get the care they need?
Symptom relief OngoingDepression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 09, 2026 15:00 UTC
-
New program aims to restore intimacy after cancer radiation
Symptom relief PausedThis study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 09, 2026 15:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief OngoingThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief PausedThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New digital coaching aims to ease cancer pain and cut opioid risks
Symptom relief OngoingThis study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Sniffing lavender may ease biopsy pain and anxiety
Symptom relief PausedThis study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New coaching program aims to help young cancer survivors connect with friends
Symptom relief OngoingThis study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could neck adjustments relieve Cancer-Related fatigue?
Symptom relief CancelledThis trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…
Sponsor: Life University • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
New program aims to ease pain for kids battling cancer
Symptom relief OngoingThis study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…
Sponsor: University of Louisville • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Veterans with cancer get help discussing End-of-Life wishes in group sessions
Symptom relief OngoingThis study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…
Sponsor: VA Palo Alto Health Care System • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Talking therapy may offer a path away from opioids for cancer survivors
Symptom relief PausedThis pilot trial tests whether Acceptance and Commitment Therapy (ACT), a type of talking therapy, can help disease-free cancer survivors manage chronic pain and reduce long-term opioid use. Participants attend six weekly virtual sessions with a psychologist. The study focuses on…
Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Video analysis could personalize rehab for chemo nerve damage
Symptom relief By invitation onlyThis study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…
Sponsor: Seoul National University Bundang Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Intermittent fasting tested to ease radiation side effects in cancer patients
Symptom relief OngoingThis phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Acupuncture needles aim to zap cancer brain fog
Symptom relief OngoingThis phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Cancer breathlessness study: can opioids help you walk easier?
Symptom relief OngoingThis study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a sugar pill you know is fake fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief By invitation onlyThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can two existing drugs help cancer patients ditch steroids?
Symptom relief OngoingThis study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…
Phase 2 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Community health workers step in to boost palliative care for black cancer patients
Symptom relief By invitation onlyThis study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief By invitation onlyThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Can a calming drug combo bring clarity to cancer patients?
Symptom relief OngoingThis study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Can yoga ease cervical cancer treatment? small trial aims to find out
Symptom relief OngoingThis study tests whether yoga therapy can improve physical and emotional well-being in people with cervical cancer undergoing chemotherapy and radiation. About 40 participants with stage IB2 to IIIB cervical cancer will attend yoga classes or receive a DVD. The main goal is to se…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can writing about cancer help young survivors heal?
Symptom relief OngoingThis study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief OngoingThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase 2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Could a single doctor visit reduce cancer distress?
Symptom relief By invitation onlyThis study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…
Sponsor: Ellis Medicine • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief PausedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase 2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could an herbal patch ease pain after cancer?
Symptom relief OngoingThis study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief By invitation onlyThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New radiation technique aims to cut side effects for uterine cancer patients
Symptom relief OngoingThis study tests a newer type of radiation therapy called online adaptive radiotherapy (oART) for people who have had surgery for endometrial or cervical cancer. The goal is to see if using smaller treatment margins can reduce side effects while still effectively targeting any re…
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to tackle loneliness in cancer survivors
Symptom relief By invitation onlyThis study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Can exercising at home match gym sessions for cancer recovery?
Symptom relief OngoingThis study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…
Sponsor: Inland Norway University of Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Talking hope: new therapy aims to lift spirits of cancer patients during radiation
Symptom relief By invitation onlyThis study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…
Sponsor: Saglik Bilimleri Universitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can a virtual sleep program help cancer survivors beat insomnia?
Symptom relief OngoingThis study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Magic mushroom compound tested for Cancer-Related depression
Symptom relief OngoingThis study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Fitbit and app aim to boost activity in cancer survivors
Symptom relief OngoingThis study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…
Sponsor: The University of Tennessee, Knoxville • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New toolkit aims to boost recovery for older cancer surgery patients
Symptom relief OngoingThis study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can an iPad program help older cancer patients stay strong?
Symptom relief OngoingThis study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can a short talk therapy beat insomnia in cancer patients?
Symptom relief OngoingThis study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…
Phase 3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Exercise may soothe chemo nerve pain, trial hopes
Symptom relief OngoingThis study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…
Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fitbit for cancer care: new study tests remote exercise monitoring
Symptom relief OngoingThis study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…
Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Can online yoga help cancer survivors sleep better?
Symptom relief OngoingThis study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can yoga and relaxation help young cancer survivors? new study tests a Stress-Busting program
Symptom relief OngoingThis study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Spine adjustments tested as fatigue fix for cancer survivors
Symptom relief PausedThis pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…
Sponsor: Life University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a smartphone app help rural cancer patients beat the odds?
Symptom relief OngoingThis study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…
Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Knee pain study for cancer patients pulled before starting
Symptom relief CancelledThis study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…
Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pain relief study for cancer patients withdrawn before starting
Symptom relief CancelledThis trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…
Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New online program aims to restore sexual health in young cancer survivors
Symptom relief OngoingThis study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Exercise boosts quality of life in cancer patients, study finds
Symptom relief OngoingThis study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…
Sponsor: University of Castilla-La Mancha • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Antidepressant drug could fight cancer fatigue
Symptom relief OngoingThis phase 3 trial tests whether bupropion, a drug used for depression and smoking cessation, can reduce fatigue in 422 cancer survivors. Participants have stable disease or no evidence of cancer and report moderate to severe fatigue. They receive either bupropion or a placebo, a…
Phase 3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Texts and trackers: new study aims to get young cancer survivors moving
Symptom relief OngoingThis study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…
Sponsor: AHS Cancer Control Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app boost quality of life for young cancer patients?
Symptom relief OngoingThis study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Forest bathing tested as fatigue fix for cancer survivors
Symptom relief By invitation onlyThis study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…
Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 09, 2026 15:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study: diet and exercise may boost sleep and reduce stress in cancer survivors
Knowledge-focused OngoingThis study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused CancelledThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
A digital guide aims to help latinx cancer patients navigate genomic testing decisions
Knowledge-focused OngoingResearchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
HPV Vaccine's Long-Term effects under the microscope in costa rica
Knowledge-focused OngoingThis study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
AI helps doctors remember what matters most to cancer patients
Knowledge-focused OngoingThis study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Cancer kids show surprising strength: study reveals growth, not just trauma
Knowledge-focused OngoingThis study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
New app helps cancer patients get housing and food support
Knowledge-focused OngoingThis study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…
Phase 2 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can a short video boost cancer patients' trial know-how?
Knowledge-focused OngoingThis study enrolls 50 adults with any type of cancer to test whether watching a video and reading a handout improves their knowledge and beliefs about cancer clinical trials. Participants complete a survey before and after the educational materials to measure any change. The goal…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can cancer patients get better care at home? MD anderson investigates
Knowledge-focused PausedThis study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New tool lets young cancer patients speak up about symptoms
Knowledge-focused OngoingThis study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused PausedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused By invitation onlyThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Blood test clues could sharpen cervical cancer treatment
Knowledge-focused OngoingThis study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if the…
Sponsor: University of Campania Luigi Vanvitelli • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused By invitation onlyThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused PausedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
Knowledge-focused OngoingThis large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Gene test could personalize cancer drug dosing
Knowledge-focused OngoingThis study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Cancer clinics study how to spot Patients' hidden struggles
Knowledge-focused By invitation onlyThis study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
Knowledge-focused OngoingThis trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New DNA test aims to predict bloodstream infections in kids with cancer
Knowledge-focused OngoingThis study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Can a simple sheet of paper improve cancer care conversations?
Knowledge-focused OngoingThis study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused By invitation onlyThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Pharmacist-Led lessons may cut infection risk in chemo patients
Knowledge-focused OngoingThis trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …
Sponsor: Jordan University of Science and Technology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Virtual peer mentoring aims to boost cervical cancer screening in ethiopian HIV clinics
Knowledge-focused By invitation onlyThis study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…
Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused By invitation onlyThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Does surgery spread cervical cancer cells? new study investigates
Knowledge-focused OngoingThis study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New platform aims to personalize cancer treatment for GI patients
Knowledge-focused OngoingThis study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…
Sponsor: Brigette Ma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks cancer patients at home to improve care
Knowledge-focused OngoingThis study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lost in translation: study probes language barriers in gynecologic cancer care
Knowledge-focused OngoingThis study gives questionnaires to patients, interpreters, and healthcare professionals to understand how language and cultural differences impact care for women with gynecologic cancer. The goal is to identify barriers and improve the patient experience. About 45 people will tak…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New web tool aims to help young cancer patients plan for family future
Knowledge-focused OngoingThis study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Cancer patients' family talks about genetic surprises studied
Knowledge-focused OngoingThis study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rare surgery for recurrent cancer: how does it affect quality of life?
Knowledge-focused By invitation onlyThis study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better p…
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Microdose cancer drug test could reveal best treatments without side effects
Knowledge-focused OngoingThis early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…
Early phase 1 • Sponsor: Presage Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused CancelledThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Early phase 1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive cancer survival study launched in russia
Knowledge-focused OngoingThis study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase 2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tracks pelvic changes after radiation in women with pelvic cancer
Knowledge-focused OngoingThis study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Massive 75,000-Patient registry aims to unlock best uses of proton therapy
Knowledge-focused By invitation onlyThis registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Study questions best surgery for High-Risk endometrial cancer
Knowledge-focused OngoingThis study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can a statin tame a cancer protein? early trial seeks answers
Knowledge-focused OngoingThis early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…
Phase 1 • Sponsor: Joaquina Baranda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Electronic surveys tested for tracking radiation side effects in gynecologic cancer
Knowledge-focused OngoingThis study aims to see if it is practical to use electronic questionnaires to measure patient-reported symptoms before, during, and after radiation treatment for gynecologic cancer. About 100 English-speaking adults receiving radiation at UNC will participate. The main goal is to…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can new outreach methods boost minority enrollment in cancer trials?
Knowledge-focused OngoingThis study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New imaging dye could reveal hidden oxygen levels in cervix tumors
Knowledge-focused OngoingThis study is testing whether a special PET scan dye called 18F-FAZA can measure low oxygen levels (hypoxia) in cervix cancer tumors. About 30 adults with cervix cancer will receive the dye before starting standard treatment with radiation and chemotherapy. The goal is to see if …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused By invitation onlyThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused By invitation onlyThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Simple senior health quiz may predict chemo dangers
Knowledge-focused OngoingThis study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can tablets replace paper for senior cancer patients?
Knowledge-focused OngoingThis study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Lifestyle coaching aims to boost activity in cancer survivors
Knowledge-focused OngoingThis study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to improve cancer care for seniors
Knowledge-focused By invitation onlyThis study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New Full-Body PET scanner promises faster scans, less radiation
Knowledge-focused OngoingThis study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to better detect depression in older adults with cancer
Knowledge-focused OngoingThis study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Scientists hunt for genetic markers in ovarian, uterine, and cervical cancers
Knowledge-focused OngoingThis study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New tool aims to predict chemo risks for seniors
Knowledge-focused OngoingThis study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to improve cancer pain management
Knowledge-focused OngoingThis study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Less invasive staging for endometrial cancer put to the test
Knowledge-focused OngoingThis phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while s…
Phase 3 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New approach aims to boost cancer trial awareness and participation
Knowledge-focused OngoingThis study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Real-Time proton beam tracking could sharpen cancer therapy
Knowledge-focused OngoingThis study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …
Sponsor: Shuanghu Yuan • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
MRI tracking could make cervix cancer radiotherapy safer
Knowledge-focused OngoingThis study tracks how the tumor and nearby organs move during radiotherapy for cervix cancer. By taking many MRI scans during treatment, researchers hope to better target the tumor and spare healthy tissue. The goal is to reduce side effects and improve outcomes. The study involv…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can tumor oxygen levels predict radiation success in cervical cancer?
Knowledge-focused OngoingThis study looks at whether oxygen levels and internal pressure in cervical tumors can help predict how well radiation therapy works. Researchers measured these factors in 346 patients with cervical cancer before and during treatment. The goal is to understand why some tumors res…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Why do cancer patients fear painkillers? new study investigates
Knowledge-focused OngoingThis study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New dosing method for Kids' cancer drug aims to reduce side effects
Knowledge-focused OngoingThis study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused By invitation onlyThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Light therapy under the microscope: can it soothe mouth sores after transplant?
Knowledge-focused OngoingThis study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Expert panel boosts precision cancer care in new study
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New imaging agent could help spot tumors in future cancer trials
Knowledge-focused OngoingThis early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
ERs could help catch cervical cancer earlier
Knowledge-focused OngoingThis study looks at whether offering cervical cancer screening in the emergency department helps more people get tested. About 200 women and transgender/non-binary individuals with a cervix, aged 25-65, will be offered a self-sampling kit or clinic referral. Researchers will call…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused CancelledThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Pandemic delays led to fewer cancer diagnoses, study of 438,000 cases shows
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Young cancer survivors face hidden financial toll
Knowledge-focused By invitation onlyThis study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can laughter yoga and art therapy ease cancer distress?
Knowledge-focused By invitation onlyThis study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…
Sponsor: La Tour Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Stem cells may unlock mystery of chemo-related heart damage
Knowledge-focused OngoingThis study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New online tool aims to help older cancer patients get better treatment plans
Knowledge-focused OngoingThis study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Could your genes raise your lung cancer risk? new study investigates
Knowledge-focused OngoingThis study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study tracks ovarian health after chemo in young women
Knowledge-focused OngoingThis study follows 196 women aged 11-35 who are receiving chemotherapy for cancer. Researchers measure hormone levels and ovarian follicles before, during, and after treatment to see how the ovaries are affected. The goal is to better understand the risk of early menopause and fe…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Cancer Patients' vaccine response under microscope
Knowledge-focused OngoingThis study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Blood test may replace tissue biopsies for ovarian cancer monitoring
Knowledge-focused OngoingThis study looks at whether a simple blood test (liquid biopsy) can track how ovarian cancer changes over time, instead of taking multiple tissue samples. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to two years. The goal is to…
Sponsor: Institut de Cancérologie de Lorraine • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:28 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Simple blood test may reveal how far cancer has spread
Knowledge-focused OngoingThis study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…
Sponsor: Çanakkale Onsekiz Mart University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC